Skip to main content
NCBI home page
Springer logoLink to Springer
. 2020 Jun 11;86(1):163. doi: 10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

R B Verheijen 1,✉, E L Swart 1, J H Beijnen 1,2, J H M Schellens 2,3, A D R Huitema 1,4, N Steeghs 3
PMCID: PMC7645546  PMID: 32524189

Correction to: Cancer Chemother Pharmacol (2017) 80:1171–1178 10.1007/s00280-017-3463-x

In the original publication of the article, the second author name has been misspelled as L. E. Swart. The correct name should read as E. L. Swart.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Cancer Chemotherapy and Pharmacology are provided here courtesy of Springer

RESOURCES